CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2014—MyCartis announced the launch of Evalution, a digital multiplex analysis platform tailored to clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic-acid-based biomarkers. Evalution provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay.
Biocartis’ Swiss business unit Evalution and Belgian-based Pronota have recently joined forces in MyCartis. The combination of the Evalution platform as designed by Biocartis and Pronota’s portfolio of validated biomarkers will deliver state-of-the-art solutions for a range of diseases in the fields of cardiovascular and women’s health, the company said in a statement.
MyCartis, +32 9 241 11 40